The Importance of MITF Signaling Pathway in the Regulation of Proliferation and Invasiveness of Malignant Melanoma
Authors:
P. Urban; M. Rabajdová; B. Veliká; I. Špaková; B. Bolerázska; M. Mareková
Authors‘ workplace:
Ústav lekárskej a klinickej biochémie, LF UPJŠ v Košiciach, Slovenská republika
Published in:
Klin Onkol 2016; 29(5): 347-350
Category:
Reviews
doi:
https://doi.org/10.14735/amko2016347
Overview
Background:
Malignant melanoma is one of the most aggressive types of cancers. Melanoma is derived from pigment-producing cells, melanocytes, which are characterized by a specific survival mechanism. Microphthalmia-associated transcription factor (MITF-M) plays a role in the metabolism of melanoma and is involved in the regulation of the expression of multiple genes mediating processes such as melanogenesis, proliferation, differentiation, and melanocyte survival. The expression of this transcription factor in melanocytes is activated by several signaling pathways, and reduced expression or function of MITF-M can cause the dysregulation of anti-apoptotic mechanisms. MITF-M is also involved in matrix metalloproteinase 14 (MMP14) activity, which is responsible for shape changes in melanocytes and increases in their motility and invasiveness. Very low levels of expression of MITF-M are found in human melanocytes with an invasive phenotype, indicating that this transcription factor acts as a suppressor of the metastatic process. Cancer cells with low expression of cytosolic/nuclear β-catenin have a small amount of MITF-M 14 that is insufficient to inhibit MMP transcription. The enzyme catalyzes the degradation of laminin and fibronectin, thereby changing the shape of melanocytes, which leads to their increased mobility and invasiveness.
Aims:
This review describes the regulatory pathway of MITF-M activation, its involvement in the proliferation of transformed melanocytes, and its role in increasing the invasiveness of malignant melanoma. A detailed understanding of the MITF-M signaling pathway is highly topical and could help to develop new diagnostic and therapeutic applications for patients with malignant melanoma.
Key words:
neoplastic cell transformation – melanoma – MITF transcription factor
This work was supported by grant projects VEGA 1/0115/14 and VEGA 1/0873/16.
The authors declare they have no potential confl icts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.
Submitted:
4. 12. 2015
Accepted:
14. 6. 2016
Sources
1. Su TR, Lin JJ, Tsai CC et al. Inhibition of melanogenesis by gallic acid: possible involvement of the PI3K/Akt, MEK/ERK and Wnt/β-catenin signaling pathways in B16F10 cells. Int J Mol Sci 2013; 14 (10): 20443–20458. doi: 10.3390/ijms141020443.
2. Maddodi N, Jayanthy A, Setaluri V. Shining light on skin pigmentation: the darker and the brighter side of effects of UV radiation. Photochem Photobiol 2012; 88 (5): 1075–1082. doi: 10.1111/j.1751-1097.2012.01138.x.
3. Paillerets BB, Lesueur F, Bertolotto C. A germline oncogenic MITF mutation and tumor susceptibility. Eur J Cell Biol 2014; 93 (1–2): 71–75. doi: 10.1016/j.ejcb.2013.10.002.
4. Hartman ML, Czyz M. Pro-survival role of MITF in melanoma. J Invest Dermatol 2015; 135 (2): 352–358. doi: 10.1038/jid.2014.319.
5. Shibahara S, Takeda K, Yasumoto K et al. Microphthalmia--associated transcription factor (MITF): multiplicity in structure, function, and regulation. J Invest Dermatol Symp Proc 2001; 6 (1): 99–104.
6. Vachtenheim J, Ondrušová L. MITF expression levels in melanoma cells contribute to cell invasion and proliferation. Exp Dermatol 2015; 24 (7): 481–484. doi: 10.1111/exd.12724.
7. Eccles MR, He S, Ahn A et al. MITF and PAX3 play distinct roles in melanoma cell migration; outline of a „genetic switch“ theory involving MITF and PAX3 in proliferative and invasive phenotypes of melanoma. Front Oncol 2013; 11 (3): 229. doi: 10.3389/fonc.2013.00229.
8. Agnarsdottir M, Ponten F, Garno H et al. MITF expression in cutaneous malignant melanoma. J Mol Biomark Diagn 2012; 3 (4): 128. doi: 10.4172/2155-9929.1000128.
9. Steingrimsson E, Copeland NG, Jenkins NA. Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet 2004; 38: 365–411.
10. Nishimura EK, Granter SR, Fisher DE. Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science 2005; 307 (5710): 720–724.
11. Loercher AE, Tank EM, Delston RB et al. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol 2005; 168 (1): 35–40.
12. Gajos-Michniewicz A, Duechler M, Czyz M. MiRNA in melanoma-derived exosomes. Cancer Lett 2014; 347 (1): 29–37. doi: 10.1016/j.canlet.2014.02.004.
13. Carreira S, Goodall J, Denat L. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev 2006; 20 (24): 3426–3439.
14. Giuliano S, Ohanna M, Ballotti R et al. Advances in melanoma senescence and potential clinical application. Pigment Cell Melanoma Res 2011; 24 (2): 295–308. doi: 10.1111/j.1755-148X.2010.00820.x.
15. Giuliano S, Cheli Y, Ohanna M. Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas. Cancer Res 2010; 70: 3813–3822. doi: 10.1158/0008-5472.CAN-09-2913.
16. Sabeh F, Shimizu-Hirota R, Weiss SJ. Protease-dependent versus-independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J Cell Biol 2009; 185 (1): 11–19. doi: 10.1083/jcb.200807195.
17. Hari L, Brault V, Kléber M et al. Lineage-specific requirements of β-catenin in neural crest development. J Cell Biol 2002; 159 (5): 867–880.
18. Zeng X, Huang H, Tamai K et al. Initiation of Wnt signaling: control of wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 2008; 135 (2): 367–375.
19. Dansky WE, Curley DP, Santhanakrishnan M et al. β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 2011; 20 (6): 741–754. doi: 10.1016/j.ccr.2011.10.030.
20. Arozarena I, Bischof H, Gilby D et al. In melanoma, beta-catenin is a suppressor of invasion. Oncogene 2011; 30 (45): 4531–4543. doi: 10.1038/onc.2011.162.
21. Hoeck KS, Eichhoff OM, Schlegel NC et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 2008; 68 (3): 650–656. doi: 10.1158/0008-5472.CAN-07-2491.
22. Sahai E, Marshall CJ. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 2003; 5 (8): 711–719.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2016 Issue 5
Most read in this issue
- The Impact of High Protein Nutritional Support on Clinical Outcomes and Treatment Costs of Patients with Colorectal Cancer
- Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group
- Malignant Mesothelioma of the Tunica Vaginalis Testis. A Clinicopathologic Analysis of Two Cases with a Review of the Literature
- Multimodal Therapy of Recurrent Malignant Schwannoma